Use of single lead VDD pacing in children.

The development of transvenous ventricular pacing leads with proximal electrodes capable of atrial sensing and the recent availability of smaller generators has created the opportunity to treat children with complete AV block and normal sinus node function with a transvenous single lead VDD pacing system. Studies in adults have demonstrated this system to be efficacious with low complication rates. Transvenous single lead VDD pacemakers were implanted in ten children, aged 5-15 years, between December 1993 and April 1996, in our institution. The indications were complete AV block with severe bradycardia in 5 patients, second-degree or complete AV block following congenital heart surgery in 3, complete AV block with long QT syndrome in 1, and second-degree AV block and syncope in 1. There were no complications related to the procedure in any case. P and R wave amplitudes were measured and thresholds were determined intraoperatively on all patients. Amplitudes and thresholds were remeasured on seven patients with a mean follow-up of 17 months; Holter monitors were performed on seven patients with mean follow-up of 16 months. P and R wave amplitudes were generally diminished at follow-up compared to initial values but remained within an acceptable range for all patients. Four patients required reprogramming after pacemaker insertion, 1 received an atrial lead for dual chamber pacing, 1 required reposition for lead dislodgment, and 1 patient required a new lead for an inadequate ventricular pacing threshold. No patient had evidence of failure to sense or capture as evaluated by Holter monitoring at last follow-up. Single lead VDD pacing systems can be successfully used in properly selected children with high degree or complete AV block with normal sinus node function.

Malignant wide complex tachycardia after adenosine administration to a postoperative pediatric patient with congenital heart disease.

Adenosine has become the treatment of choice for paroxysmal supraventricular tachycardia because of its safety and efficacy. There have been no reports of malignant arrhythmias occurring after adenosine administration. This case report presents the occurrence of a malignant wide complex tachycardia after intravenous adenosine administration in a 10-year-old boy 2 days after a Fontan procedure. Thus the administration of adenosine in a critically ill postoperative patient can have morbidity or potential mortality and must be monitored closely.

Usefulness of intermittent monitoring of mixed venous oxygen saturation after stage I palliation for hypoplastic left heart syndrome.

Most deaths after stage I palliation for hypoplastic left heart syndrome have occurred within the first 24 hours after surgery. Efforts to improve 1-day survival should therefore have significant impact on improving overall survival. Early death has most often been attributed to low cardiac output and abnormalities of pulmonary to systemic flow ratio (Qp/Qs). Thirteen infants underwent stage I palliation and had a catheter inserted in the high superior vena cava (SVC) for intermittent measurement of SVC oxygen saturation. Calculation of Qp/Qs was achieved using SVC saturation as a mixed venous oxygen saturation, and estimating pulmonary venous oxygen saturation. Eleven patients survived, and 2 patients died within the first 24 hours. Abnormalities in Qp/Qs were noted in 12 of 13 patients after operation. In 10 of these 12 patients, there was a high Qp/Qs, which has been associated with poor outcome. High Qp/Qs was noted even in patients with acceptable arterial oxygen saturations (< 85%). SVC saturation increased in all survivors during the first 24 hours, and was associated with a decrease in Qp/Qs. Measurement of SVC oxygen saturation appears to be a valuable adjuvant in the postoperative management of infants after stage I palliation of hypoplastic left heart syndrome. Major abnormalities in Qp/Qs can be detected even with acceptable arterial saturations. With this information, early ventilator/pharmaceutical adjustments can be made which may improve stage I survival.

Use of adenosine in the management of perioperative arrhythmias in the pediatric cardiac intensive care unit.

OBJECTIVE: To assess the safety, efficacy, and diagnostic usefulness of iv adenosine in treating acute episodes of paroxysmal supraventricular tachycardia in critically ill infants and children with congenital heart disease. DESIGN: A consecutive sample study over a 1-yr period. SETTING: A six-bed pediatric cardiac ICU at a tertiary care center. PATIENTS: Nine consecutive critically ill infants and children with congenital heart disease, either awaiting emergent surgery or in the immediate postoperative period, who had at least one episode of tachyarrhythmia treated with iv adenosine. INTERVENTIONS: In children less than 50 kg, adenosine was administered in incremental doses of 100, 200, and 300 micrograms/kg every 3 mins. Patients weighing greater than 50 kg were given doses of 6, 12, and 18 mg iv. The adenosine protocol was stopped when the arrhythmia was terminated or a mechanism of the arrhythmia was shown that would not respond to adenosine administration. MEASUREMENTS AND MAIN RESULTS: Adenosine was used 14 times in nine patients, all of whom were hemodynamically unstable before or after the development of the tachyarrhythmia. Adenosine was effective in rapidly terminating all nine episodes of paroxysmal supraventricular tachycardia, six of which occurred in patients known to have Wolff-Parkinson-White syndrome. All patients had marked hemodynamic improvement after conversion to normal sinus rhythm. In five episodes of tachyarrhythmia that did not respond to adenosine, the transient block at the atrioventricular (A-V) node helped determine the underlying arrhythmia without clinically important side-effects. CONCLUSIONS: Adenosine can be used safely and effectively in critically ill infants and children with congenital heart disease and perioperative tachyarrhythmia. More investigation into the "chemical conversion" of paroxysmal supraventricular tachycardias as well as its diagnostic value in this subset of critically ill patients is warranted.

Comparison of propofol versus ketamine for anesthesia in pediatric patients undergoing cardiac catheterization.

Intravenous propofol was compared with ketamine in 20 pediatric patients undergoing cardiac catheterization. The study patients were randomly assigned to treatment groups so that 10 patients received ketamine and 10 patients received propofol. The hemodynamic responses and recovery characteristics of the two groups were compared. On induction of anesthesia, seven patients in the propofol group experienced a transient decrease in mean arterial blood pressure greater than 20% of baseline accompanied by mild arterial desaturation in four patients. Only one patient in the ketamine group experienced such a decrease in arterial blood pressure. This was the only significant difference (P less than 0.05) in hemodynamic effects between the two groups. Time to full recovery (mean +/- SD) was significantly less in the propofol group (24 +/- 19 min vs 139 +/- 87 min, P less than 0.001). In the ketamine group only, significant correlations (P less than 0.05) included time to full recovery with duration of anesthetic (r = 0.71) and time to full recovery with total drug dose per kilogram (r = 0.82). The authors conclude that propofol anesthesia is a practical alternative for pediatric patients undergoing elective cardiac catheterization and may be preferable to ketamine because of the significantly shorter recovery time.